Latest news and press releases about NeuroSense Therapeutics Ltd. (NRSN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
Price
| Price | $6.49 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | -5.76 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1070.23% |
| Return on Invested Capital | 797.48% |
| Return on Assets | -1082.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRSN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks